Related Experiment Video
Updated: Jun 9, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Host-pathobiont interactions in Crohn's disease
Roberta Caruso1, Bernard C Lo2, Grace Y Chen3
1Department of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. rocaruso@med.umich.edu.
Certain gut microbes (pathobionts) may trigger Crohn's disease by invading intestinal tissue. Host genetics and microbial location, like the mucus layer, are key factors in developing this inflammatory bowel disease.
Area of Science:
- Microbiology
- Gastroenterology
- Immunology
Background:
- The mammalian intestine hosts a complex gut microbiota, essential for host health.
- Dysbiosis, or imbalance, in the gut microbiota is linked to inflammatory bowel diseases like Crohn's disease.
- The specific roles of pathobionts in Crohn's disease pathogenesis are not fully understood.
Purpose of the Study:
- To review the distinct niches occupied by intestinal symbionts and pathobionts.
- To explore how pathobionts trigger inflammation in Crohn's disease.
- To discuss the impact of host genetics on intestinal homeostasis and pathobiont accumulation.
Main Methods:
- Review of existing literature and animal models.
- Analysis of pathobiont localization within the intestinal environment (mucus layer, epithelium).
- Examination of host genetic factors influencing intestinal barrier function and immune response.
Main Results:
- Evidence suggests pathobionts associated with Crohn's disease reside in specific niches, such as the mucus layer or near the intestinal epithelium.
- Host genetic mutations in Crohn's disease can disrupt intestinal homeostasis, facilitating pathobiont penetration and accumulation.
- These pathobionts can trigger inflammatory responses contributing to colitis.
Conclusions:
- Pathobionts residing in specific intestinal niches play a critical role in Crohn's disease development.
- Host genetic susceptibility influences the interaction between the microbiota and the intestinal environment.
- Microbiome-based interventions offer potential for precision therapeutic strategies in Crohn's disease treatment.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

